Symbols

PROF

Profound Medical·NASDAQ

--(--)

PROF fundamentals

PROF Q4 2025 Earnings

Profound Medical (PROF) released its earnings on Mar 5, 2026: revenue was 5.98M (YoY +43.09%), missed estimates; EPS was -0.27 (YoY -35.00%), beat estimates.

Revenue / YoY

5.98M

+43.09%

EPS / YoY

-0.27

-35.00%

Report date

Mar 5, 2026

PROF Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue up 43% YoY to $6 million, driven by 15% recurring revenue growth and 3.7 million in capital sales.
Clinical Momentum: CAPTAIN trial 6-month data to show TULSA's superior quality of life vs. robotic surgery, with 91% prostate volume reduction in TACT trial.
BPH Expansion: New AI module reduces BPH procedure time to 60-90 minutes, tripling TAM to 400,000+ patients.
Profitability Path: Target 120 TULSA-PRO sites by end-2026, $85 million annual revenue with 70%+ gross margin.
Cash Flow: Q4 2025 cash burn of $6.5 million, down 35% YoY, with 2026 installations expected to accelerate cash flow positivity.

Earnings

EPS

Revenue

Revenue & Expenses

PROF has released its 2025 Q4 earnings report, with revenue of 5.98M, reflecting a YoY change of 43.13%, and net profit of -8.18M, showing a YoY change of -65.25%. The Sankey diagram below clearly presents PROF's revenue sources and cost distribution.

Key Indicators

Profound Medical (PROF) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Profound Medical (PROF)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Profound Medical (PROF)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Profound Medical (PROF)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown